PL352899A1 - Postacie polimorficzne krystalicznego chlorku (2-benzhydrylo-1-azabicyklo[2.2.2]okt-3-ylo)-(5-izopropylo-2-metoksybenzylo)amoniowego jako antagoniścireceptora NK-1 - Google Patents
Postacie polimorficzne krystalicznego chlorku (2-benzhydrylo-1-azabicyklo[2.2.2]okt-3-ylo)-(5-izopropylo-2-metoksybenzylo)amoniowego jako antagoniścireceptora NK-1Info
- Publication number
- PL352899A1 PL352899A1 PL00352899A PL35289900A PL352899A1 PL 352899 A1 PL352899 A1 PL 352899A1 PL 00352899 A PL00352899 A PL 00352899A PL 35289900 A PL35289900 A PL 35289900A PL 352899 A1 PL352899 A1 PL 352899A1
- Authority
- PL
- Poland
- Prior art keywords
- ammoniumchloride
- benzhydryl
- azabicyclo
- polymorphs
- methoxybenzyl
- Prior art date
Links
- AXFGBGHZCXQFRG-UHFFFAOYSA-N 2-benzhydryl-n-[(2-methoxy-5-propan-2-ylphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine;hydrochloride Chemical compound Cl.COC1=CC=C(C(C)C)C=C1CNC1C(C(C=2C=CC=CC=2)C=2C=CC=CC=2)N2CCC1CC2 AXFGBGHZCXQFRG-UHFFFAOYSA-N 0.000 title 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14023399P | 1999-06-22 | 1999-06-22 | |
| PCT/IB2000/000756 WO2000078759A1 (en) | 1999-06-22 | 2000-06-06 | Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL352899A1 true PL352899A1 (pl) | 2003-09-22 |
Family
ID=22490317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL00352899A PL352899A1 (pl) | 1999-06-22 | 2000-06-06 | Postacie polimorficzne krystalicznego chlorku (2-benzhydrylo-1-azabicyklo[2.2.2]okt-3-ylo)-(5-izopropylo-2-metoksybenzylo)amoniowego jako antagoniścireceptora NK-1 |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US6262067B1 (pl) |
| EP (1) | EP1187834A1 (pl) |
| JP (1) | JP2003502425A (pl) |
| KR (1) | KR20020030280A (pl) |
| CN (1) | CN1390216A (pl) |
| AP (1) | AP2001002367A0 (pl) |
| AR (1) | AR024411A1 (pl) |
| AU (1) | AU767336B2 (pl) |
| BG (1) | BG106205A (pl) |
| BR (1) | BR0011835A (pl) |
| CA (1) | CA2375265A1 (pl) |
| CO (1) | CO5190663A1 (pl) |
| CZ (1) | CZ20014458A3 (pl) |
| DZ (1) | DZ3055A1 (pl) |
| EA (1) | EA004264B1 (pl) |
| EC (1) | ECSP003538A (pl) |
| EE (1) | EE200100698A (pl) |
| HR (1) | HRP20010920A2 (pl) |
| HU (1) | HUP0201694A3 (pl) |
| IL (1) | IL146410A0 (pl) |
| IS (1) | IS6161A (pl) |
| MA (1) | MA26744A1 (pl) |
| MX (1) | MXPA02000033A (pl) |
| NO (1) | NO20016187D0 (pl) |
| NZ (1) | NZ515348A (pl) |
| OA (1) | OA11952A (pl) |
| PA (1) | PA8496701A1 (pl) |
| PE (1) | PE20010322A1 (pl) |
| PL (1) | PL352899A1 (pl) |
| SK (1) | SK18672001A3 (pl) |
| TN (1) | TNSN00137A1 (pl) |
| TR (1) | TR200103688T2 (pl) |
| UY (1) | UY26211A1 (pl) |
| WO (1) | WO2000078759A1 (pl) |
| ZA (1) | ZA200110387B (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387925B1 (en) * | 1999-06-01 | 2002-05-14 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions |
| US6939873B2 (en) * | 2000-07-26 | 2005-09-06 | Taro Pharmaceuticals Industries Limited | Non-sedating barbituric acid derivatives |
| US7683071B2 (en) * | 2000-07-26 | 2010-03-23 | Taro Pharmaceuticals Industries Ltd. | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
| US6756379B2 (en) * | 2001-07-26 | 2004-06-29 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
| JP2006503859A (ja) * | 2002-10-04 | 2006-02-02 | メルク シャープ エンド ドーム リミテッド | 受容体拮抗薬としてのアザ二環式スピロエーテル誘導体 |
| ES2315569T3 (es) * | 2002-12-11 | 2009-04-01 | Taro Pharmaceutical Industries Ltd. | Procedimiento de tratamiento de trastornos del movimiento usando derivados de acido barbiturico. |
| CA2572797A1 (en) * | 2004-07-02 | 2006-01-12 | Daniella Gutman | A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid |
| EP2081576A4 (en) * | 2006-11-14 | 2010-06-30 | Taro Pharmaceuticals North Ame | METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES |
| UA102128C2 (en) * | 2008-12-05 | 2013-06-10 | Х. Луннбек А/С | Nalmefene hydrochloride dihydrate |
| BR112021024330A2 (pt) * | 2019-06-03 | 2022-01-11 | Biotheryx Inc | Sais cristalinos não higroscópicos de um composto de pirazol, e composições farmacêuticas e uso dos mesmos |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX18467A (es) * | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
| UA27776C2 (uk) * | 1991-05-31 | 2000-10-16 | Пфайзер Інк. | Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців |
| DK0668863T3 (da) * | 1992-11-12 | 1997-06-30 | Pfizer | Quinuclidinderivat som substans P-antagonist |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
-
2000
- 2000-05-04 US US09/564,528 patent/US6262067B1/en not_active Expired - Fee Related
- 2000-06-06 NZ NZ515348A patent/NZ515348A/en unknown
- 2000-06-06 CN CN00809305A patent/CN1390216A/zh active Pending
- 2000-06-06 TR TR2001/03688T patent/TR200103688T2/xx unknown
- 2000-06-06 EP EP00929745A patent/EP1187834A1/en not_active Withdrawn
- 2000-06-06 OA OA1200100314A patent/OA11952A/en unknown
- 2000-06-06 PA PA20008496701A patent/PA8496701A1/es unknown
- 2000-06-06 WO PCT/IB2000/000756 patent/WO2000078759A1/en not_active Ceased
- 2000-06-06 HU HU0201694A patent/HUP0201694A3/hu unknown
- 2000-06-06 CA CA002375265A patent/CA2375265A1/en not_active Abandoned
- 2000-06-06 IL IL14641000A patent/IL146410A0/xx unknown
- 2000-06-06 EA EA200101179A patent/EA004264B1/ru not_active IP Right Cessation
- 2000-06-06 AP APAP/P/2001/002367A patent/AP2001002367A0/en unknown
- 2000-06-06 EE EEP200100698A patent/EE200100698A/xx unknown
- 2000-06-06 SK SK1867-2001A patent/SK18672001A3/sk unknown
- 2000-06-06 BR BR0011835-4A patent/BR0011835A/pt not_active IP Right Cessation
- 2000-06-06 PL PL00352899A patent/PL352899A1/pl not_active Application Discontinuation
- 2000-06-06 KR KR1020017016407A patent/KR20020030280A/ko not_active Ceased
- 2000-06-06 CZ CZ20014458A patent/CZ20014458A3/cs unknown
- 2000-06-06 JP JP2001504925A patent/JP2003502425A/ja active Pending
- 2000-06-06 MX MXPA02000033A patent/MXPA02000033A/es unknown
- 2000-06-06 AU AU47745/00A patent/AU767336B2/en not_active Ceased
- 2000-06-06 HR HR20010920A patent/HRP20010920A2/hr not_active Application Discontinuation
- 2000-06-13 CO CO00043885A patent/CO5190663A1/es not_active Application Discontinuation
- 2000-06-20 PE PE2000000613A patent/PE20010322A1/es not_active Application Discontinuation
- 2000-06-20 AR ARP000103053A patent/AR024411A1/es not_active Application Discontinuation
- 2000-06-20 UY UY26211A patent/UY26211A1/es not_active Application Discontinuation
- 2000-06-21 DZ DZ000113A patent/DZ3055A1/xx active
- 2000-06-21 TN TNTNSN00137A patent/TNSN00137A1/fr unknown
- 2000-06-21 MA MA26007A patent/MA26744A1/fr unknown
- 2000-06-22 EC EC2000003538A patent/ECSP003538A/es unknown
-
2001
- 2001-11-13 IS IS6161A patent/IS6161A/is unknown
- 2001-12-10 BG BG106205A patent/BG106205A/bg unknown
- 2001-12-18 NO NO20016187A patent/NO20016187D0/no not_active Application Discontinuation
- 2001-12-19 ZA ZA200110387A patent/ZA200110387B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6751301A (en) | 1,3,8-triaza-spiro'4,5]decan-4-one derivatives as neurokinin receptor antagonists | |
| PL342692A1 (en) | Derivatives of 2-arylethyl-(piperidin-4-ylmethyl)amine as antagonists of muscarinic receptor | |
| PL356990A1 (pl) | Pochodne izoksazolokarboksyamidu | |
| HUP0202034A2 (en) | Heterocyclic substituted aminoazacycles useful as central nervous system agents | |
| PL340282A1 (en) | Novel derivatives of cyclopentene useful as antagonists of motilin receptor | |
| IL146410A0 (en) | Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2] oct-3-yl)-(1so-propyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists | |
| IL142045A0 (en) | Naphthalenecarboxamides as tachykinin receptor antagonists | |
| IL148623A0 (en) | Thienoisoxazolyl-and thienylpyrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists | |
| PL335100A1 (en) | Oxazolynones as antagonists of 5ht2a receptor | |
| PL350536A1 (en) | Biphenyl derivatives as antagonists of the neurokinine-1 receptor | |
| AU1296899A (en) | Phenyl-alkyl-imidazoles as h3 receptor antagonists | |
| GR3034847T3 (en) | Indoline derivatives useful as 5-ht-2c receptor antagonists | |
| AU1100300A (en) | Piperidyloxadiazoles as dopamine receptor antagonists | |
| IL145952A0 (en) | Polymorphs of crystalline (2-benzhydryl-1-azabicyclo [2.2.2.] oct-3-yl) - (5-iso-propyl-2-methoxybenzyl) - amine citrate as nk-1 receptor antagonists | |
| PL330796A1 (en) | Derivatives of indolin useful as antagonists of 5-ht-2c receptor | |
| AU1566499A (en) | Imidazol derivatives as muscarinic m3 receptor antagonists | |
| AU2574801A (en) | Selective iGLUR5 receptor antagonists | |
| IL139262A (en) | Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists | |
| IL135809A0 (en) | Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein | |
| AU5966098A (en) | NK-1 receptor antagonists for the treatment of delayed emesis | |
| SI0912556T1 (en) | Indoline derivatives useful as 5-ht-2c receptor antagonists | |
| GB9814737D0 (en) | Fibrinogen receptor antagonists | |
| TW422077U (en) | Improved structure of chuck for mop | |
| AU2512800A (en) | Alpha1-adrenergic receptor antagonists | |
| HK1025969A (en) | Phenyl-alkyl-imidazoles as h3 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |